Investor Presentation

Investor Presentation - Q2 & H1 FY27 - Q2 revenue Rs 755 Cr +17.45% y-y; EBITDA Rs 132 Cr +273% y-y; EBITDA margin 17.45% +897 bps y-y; PAT Rs 89 Cr +117% y-y - H1 revenue Rs 1330 Cr +57% y-y; EBITDA Rs 220 Cr +177% y-y; EBITDA margin 16.5% +894 bps y-y; PAT Rs 145 Cr +243% y-y - CDMO business scaled up, crossing 52% of API+CDMO revenue in Q2 - Export revenue up 122% y-y in H1, now ~50% of sales; domestic business growing selectively - Stronger earnings profile with ROCE 18.8% and ROE 13.6% TTM, improved working capital and debt/equity 0.23x - Medical devices segment revenue Rs 208 Cr in Q2 (+65% y-y), Rs 399 Cr in H1 (+39% y-y) - Capacity expansion ahead of schedule with 614 KL commissioned for global programmes - Focus on higher-value APIs, innovation hub, and longer-duration global partnerships